{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:03:38Z","timestamp":1793232218145,"version":"4.5.0"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Astatine-211 (\n                    <jats:sup>211<\/jats:sup>\n                    At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2022.1076210","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T11:19:09Z","timestamp":1673003949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":98,"title":["Astatine-211 based radionuclide therapy: Current clinical trial landscape"],"prefix":"10.3389","volume":"9","author":[{"given":"Per","family":"Albertsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bergmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hallqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Aneheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sture","family":"Lindegren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Timperanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Smerud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1103\/PhysRev.57.459","article-title":"Possible production of radioactive isotopes of element 85","volume":"57","author":"Corson","year":"1940","journal-title":"Phys Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3181\/00379727-86-21100","article-title":"Accumulation of astatine211 by thyroid gland in man","volume":"86","author":"Hamilton","year":"1954","journal-title":"Proc Soc Exp Biol Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","article-title":"Production, purification and availability of (211)At: near term steps towards global access","volume":"100","author":"Feng","year":"2021","journal-title":"Nucl Med Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/cbr.2019.3055","article-title":"Realizing clinical trials with astatine-211: the chemistry infrastructure","volume":"35","author":"Lindegren","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1021\/acs.accounts.1c00327","article-title":"Advances in the chemistry of astatine and implications for the development of radiopharmaceuticals","volume":"54","author":"Gu\u00e9rard","year":"2021","journal-title":"Acc Chem Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnumed.121.262687","article-title":"Harnessing \u03b1-emitting radionuclides for therapy: radiolabeling method review","volume":"63","author":"Yang","year":"2022","journal-title":"J Nucl Med."},{"key":"B7","first-page":"124","article-title":"Endoarterielle therapie eines zungenkarzinoms mit 211 at-markierten humanserumalbumin-mikrosph\u00e4ren\u2014erste klinische erfahrungen","volume":"21","author":"Doberenz","year":"1990","journal-title":"NucCompact."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2\u2013a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2967\/jnumed.118.220384","article-title":"Intraperitoneal alpha-emitting radioimmunotherapy with (211)At in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations","volume":"60","author":"Hallqvist","year":"2019","journal-title":"J Nucl Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijrobp.2015.07.005","article-title":"Absorbed doses and risk estimates of (211)At-MX35 F(ab')2 in intraperitoneal therapy of ovarian cancer patients","volume":"93","author":"Cederkrantz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263349","article-title":"Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy","author":"Leidermark","year":"2022","journal-title":"J Nucl Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2307\/3579925","article-title":"The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro","volume":"149","author":"Larsen","year":"1998","journal-title":"Radiat Res."},{"key":"B14","first-page":"2495","article-title":"Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent","volume":"4","author":"Reist","year":"1998","journal-title":"Clin Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0969-8051(97)00060-7","article-title":"Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate","volume":"24","author":"Zalutsky","year":"1997","journal-title":"Nucl Med Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0360-3016(99)00206-0","article-title":"Radiotoxicity of systemically administered 211At-labeled human\/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis","volume":"45","author":"McLendon","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1200\/JCO.1998.16.6.2202","article-title":"Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results","volume":"16","author":"Bigner","year":"1998","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2002.20.5.1389","article-title":"Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas","volume":"20","author":"Reardon","year":"2002","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2967\/jnumed.115.167825","article-title":"Biokinetic modeling and dosimetry for optimizing intraperitoneal radioimmunotherapy of ovarian cancer microtumors","volume":"57","author":"Palm","year":"2016","journal-title":"J Nucl Med."},{"key":"B21","article-title":"Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model","author":"Andersson","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B22","first-page":"1342","article-title":"Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose","volume":"47","author":"Elgqvist","year":"2006","journal-title":"J Nucl Med."},{"key":"B23","first-page":"1907","article-title":"Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35","volume":"46","author":"Elgqvist","year":"2005","journal-title":"J Nucl Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/cbr.2009.0628","article-title":"Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice","volume":"24","author":"Back","year":"2009","journal-title":"Cancer Biother Radiopharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1089\/cbr.2012.1184","article-title":"Evaluation of effects on the peritoneum after intraperitoneal alpha-radioimmunotherapy with (211)At","volume":"27","author":"Cederkrantz","year":"2012","journal-title":"Cancer Biother Radiopharm."},{"key":"B26","first-page":"464","article-title":"Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice","volume":"46","author":"Elgqvist","year":"2005","journal-title":"J Nucl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.icrp.2007.10.003","article-title":"ICRP publication 103","volume":"37","year":"2007","journal-title":"Ann ICRP"},{"key":"B28","unstructured":"Home - ClinicalTrials.gov2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0205135","DOI":"10.1371\/journal.pone.0205135","article-title":"cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies","volume":"13","author":"Li","year":"2018","journal-title":"PLoS ONE."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-22-0400","article-title":"Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma","volume":"28","author":"Batra","year":"2022","journal-title":"Clin Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","article-title":"Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation","volume":"119","author":"Chen","year":"2012","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-08-4363","article-title":"Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211","volume":"69","author":"Nakamae","year":"2009","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2012-11-467035","article-title":"Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model","volume":"121","author":"Orozco","year":"2013","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/S2666-6367(21)00083-X","article-title":"57 - a phase I trial of first-in-human alpha-emitter astatine-211-labeled anti-CD45 antibody (211At-BC8-B10) in combination with fludarabine and TBI As conditioning for allogeneic hematopoietic cell transplantation (HCT) for patients with refractory\/relapsed leukemia or high-risk myelodysplastic syndrome (MDS): preliminary results of dose escalation","volume":"27","author":"Sandmaier","year":"2021","journal-title":"Transplant Cell Therapy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.2967\/jnumed.115.162388","article-title":"Alpha-imaging confirmed efficient targeting of CD45-positive cells after 211At-radioimmunotherapy for hematopoietic cell transplantation","volume":"56","author":"Frost","year":"2015","journal-title":"J Nucl Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jtct.2021.02.018","article-title":"Addition of astatine-211-labeled anti-CD45 antibody to TBI as conditioning for DLA-identical marrow transplantation: a novel strategy to overcome graft rejection in a canine presensitization model: \u201cradioimmunotherapy to overcome transfusion-induced sensitization\u201d","volume":"27","author":"Nakaya","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B38","unstructured":"At-211 user meeting 2021_final_combo_Li & Emory_sm\n            LiY\n          2022"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","article-title":"A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies","volume":"74","author":"Green","year":"2014","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3390\/cancers14174169","article-title":"Targeting CD38 in neoplasms and non-cancer diseases","volume":"14","author":"Szlasa","year":"2022","journal-title":"Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/blood.2019001250","article-title":"The alpha-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model","volume":"134","author":"O'Steen","year":"2019","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2967\/jnumed.118.222638","article-title":"Enhancement of (211)At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha-therapy of thyroid cancer","volume":"60","author":"Watabe","year":"2019","journal-title":"J Nucl Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"100757","DOI":"10.1016\/j.tranon.2020.100757","article-title":"Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [(211)At] NaAt in mice: a revisit","volume":"13","author":"Liu","year":"2020","journal-title":"Transl Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12149-021-01612-9","article-title":"Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12149-021-01619-2","article-title":"Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0969-8051(96)00115-1","article-title":"Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model","volume":"23","author":"Vaidyanathan","year":"1996","journal-title":"Nucl Med Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B48","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","article-title":"Preclinical evaluation of the acute radiotoxicity of the alpha-emitting molecular-targeted therapeutic agent (211)At-MABG for the treatment of malignant pheochromocytoma in normal mice","volume":"12","author":"Sudo","year":"2019","journal-title":"Transl Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12149-022-01765-1","article-title":"Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"36","author":"Ukon","year":"2022","journal-title":"Ann Nucl Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2191-219X-3-23","article-title":"Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb","volume":"3","author":"Eriksson","year":"2013","journal-title":"EJNMMI Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/cbr.2014.1625","article-title":"Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model","volume":"29","author":"Eriksson","year":"2014","journal-title":"Cancer Biother Radiopharm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/acs.molpharmaceut.2c00349","article-title":"Targeted alpha therapy of glioma using (211)At-labeled heterodimeric peptide targeting both VEGFR and integrins","volume":"19","author":"Liu","year":"2022","journal-title":"Mol Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.05.008","volume":"53","author":"Lyczko","year":"2017","journal-title":"Nucl Med Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.18632\/oncotarget.27552","article-title":"Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: a preclinical study in glioma bearing mice","volume":"11","author":"Watabe","year":"2020","journal-title":"Oncotarget."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/MLG.0b013e31804b1a6d","article-title":"Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma","volume":"117","author":"Cheng","year":"2007","journal-title":"Laryngoscope."},{"key":"B56","article-title":"Preparation and evaluation of 211At labelled antineoplastic antibodies","author":"Walte","year":"2007","journal-title":"J Pharm Pharm Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.1038\/s41598-020-63557-9","article-title":"Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using (211)At-CXCR4 monoclonal antibody","volume":"10","author":"Oriuchi","year":"2020","journal-title":"Sci Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","article-title":"Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model","volume":"125","author":"Green","year":"2015","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.bmc.2018.01.023","article-title":"Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment","volume":"26","author":"Zhao","year":"2018","journal-title":"Bioorg Med Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/0959-8049(96)00236-5","article-title":"211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage","author":"Link","year":"1996","journal-title":"Eur J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/cancers12092721","article-title":"Targeted-alpha-therapy combining astatine-211 and anti-CD138 antibody in a preclinical syngeneic mouse model of multiple myeloma","volume":"12","author":"Gouard","year":"2020","journal-title":"Min Res Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s42003-022-04209-8","article-title":"Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma","volume":"5","author":"Makvandi","year":"2022","journal-title":"Commun Biol."},{"key":"B63","first-page":"459","article-title":"Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18","volume":"20","author":"Andersson","year":"2000","journal-title":"Anticancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100873","DOI":"10.1016\/j.tranon.2020.100873","article-title":"Evaluation of therapeutic efficacy of (211)At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer","volume":"14","author":"Palm","year":"2020","journal-title":"Transl Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.nucmedbio.2006.07.009","article-title":"Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity","volume":"33","author":"Elgqvist","year":"2006","journal-title":"Nucl Med Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nucmedbio.2011.07.003","article-title":"Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"39","author":"Gustafsson","year":"2012","journal-title":"Nucl Med Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijrobp.2007.06.023","article-title":"Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice","volume":"69","author":"Palm","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/cas.13282","article-title":"Locoregional therapy with alpha-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1021\/acs.molpharmaceut.9b00354","article-title":"Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior","volume":"16","author":"Dekempeneer","year":"2019","journal-title":"Mol Pharm."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264071.","article-title":"Effective treatment of human breast carcinoma xenografts with single-dose (211)At-labeled anti-HER2 single domain antibody fragment","author":"Feng","year":"2022","journal-title":"J Nucl Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/1078-0432.CCR-07-1250","article-title":"Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2\/neu diabodies","volume":"14","author":"Robinson","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","volume":"57","author":"Kiess","year":"2016","journal-title":"J Nucl Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13550-020-0600-z","article-title":"Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors","volume":"10","author":"B\u00e4ck","year":"2020","journal-title":"EJNMMI Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1248\/cpb.c20-00077","article-title":"Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy","volume":"68","author":"Aoki","year":"2020","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"B75","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0969-8051(02)00332-3","article-title":"Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells","volume":"29","author":"Carlin","year":"2002","journal-title":"Nucl Med Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00259-002-0784-7","article-title":"Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium\/iodide symporter","volume":"29","author":"Petrich","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/1078-0432.CCR-05-1576","article-title":"Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium\/iodide symporter-expressing tumors","volume":"12","author":"Petrich","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/jnt2040012","article-title":"Surface adsorption of the alpha-emitter astatine-211 to gold nanoparticles is stable in vivo and potentially useful in radionuclide therapy","volume":"2","author":"Sporer","year":"2021","journal-title":"J Nanotheran."},{"key":"B79","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","article-title":"Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers","volume":"55","author":"Eso","year":"2020","journal-title":"J Gastroenterol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3390\/cancers14143418","article-title":"Individualization of radionuclide therapies: challenges and prospects","volume":"14","author":"Piwowarska-Bilska","year":"2022","journal-title":"Cancers"},{"key":"B83","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/02841860500355900a","article-title":"Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the nordic gastrointestinal tumour adjuvant therapy group","volume":"44","author":"Glimelius","year":"2005","journal-title":"Acta Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2967\/jnumed.116.178327","article-title":"Cure of human ovarian carcinoma solid xenografts by fractionated alpha-radioimmunotherapy with (211)At-MX35-F(ab')2: influence of absorbed tumor dose and effect on long-term survival","volume":"58","author":"Back","year":"2017","journal-title":"J Nucl Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood-2011-04-347039","article-title":"Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model","volume":"118","author":"Pagel","year":"2011","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted imaging and therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J Nucl Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: a path forward for radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J Nuc Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/1874471011104030248","article-title":"Pretargeted radioimmunotherapy with alpha-particle emitting radionuclides","volume":"4","author":"Lindegren","year":"2011","journal-title":"Curr Radiopharm."},{"key":"B89","first-page":"131","article-title":"Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin","volume":"41","author":"Breitz","year":"2000","journal-title":"J Nucl Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current landscape in clinical pretargeted radioimmunoimaging and therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J Nucl Med."},{"key":"B91","article-title":"Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial","author":"Kraeber-Bodere","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B92","first-page":"642","article-title":"Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies","volume":"46","author":"Shen","year":"2005","journal-title":"J Nucl Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1040-8428(01)00133-0","article-title":"Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL)","volume":"40","author":"Weiden","year":"2001","journal-title":"Crit Rev Oncol Hematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1535-7163.MCT-16-0503","article-title":"Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand diels-alder click chemistry","volume":"16","author":"Houghton","year":"2017","journal-title":"Mol Cancer Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13304-022-01376-5","article-title":"The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with\/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials","volume":"3","author":"Deng","year":"2022","journal-title":"Updates Surg."},{"key":"B97","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ejso.2022.01.012","article-title":"Anatomic sites of disease in colorectal cancer patients recorded at the time of cytoreductive surgery for peritoneal metastases","volume":"48","author":"Sugarbaker","year":"2022","journal-title":"Eur J Surg Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","article-title":"Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review","volume":"20","author":"Honor\u00e9","year":"2013","journal-title":"Ann Surg Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/bjs5.46","article-title":"Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma","volume":"2","author":"Schorn","year":"2018","journal-title":"BJS Open."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.110.080226","article-title":"Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of non-internalizing 125I-Labeled","volume":"51","author":"Boudousq","year":"2010","journal-title":"Monoclonal Antibodies."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2967\/jnumed.118.208611","article-title":"Radiolabeled antibodies against m\u00fcllerian-inhibiting substance receptor, type II: new tools for a theranostic approach in ovarian cancer","volume":"59","author":"Deshayes","year":"2018","journal-title":"J Nuc Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J Clin Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J Neurooncol."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00259-010-1633-8","article-title":"Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid","volume":"38","author":"He","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2967\/jnumed.108.060798","article-title":"pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases","volume":"50","author":"Lv","year":"2009","journal-title":"J Nucl Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.2967\/jnumed.118.219576","article-title":"Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors","volume":"60","author":"Pandit-Taskar","year":"2019","journal-title":"J Nucl Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00259-020-05050-z","article-title":"IntraOmmaya compartmental radioimmunotherapy using (131)I-omburtamab-pharmacokinetic modeling to optimize therapeutic index","volume":"48","author":"Yerrabelli","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B109","volume-title":"Modelling show alpha-emitter astatine-211 is an apposite candidate for intra-thecal radioimmunotherapy of neuroblastoma metastasized to the central nervous system. In European Association of Nuclear Medicine October 22 \u2013 30, 2020 Virtual 2020 2020\/09\/01. European Journal of Nuclear Medicine and Molecular Imaging","author":"Palm","year":"2020"},{"key":"B110","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2967\/jnumed.117.201285","article-title":"Model of intraperitoneal targeted alpha-particle therapy shows that posttherapy cold-antibody boost enhances microtumor radiation dose and treatable tumor sizes","volume":"59","author":"Palm","year":"2018","journal-title":"J Nucl Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1118\/1.1640951","article-title":"Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion","volume":"31","author":"Palm","year":"2004","journal-title":"Med Phys."},{"key":"B112","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/0020-708X(81)90078-8","article-title":"The biological behaviour of some organic astatine compounds in rats","volume":"32","author":"Visser","year":"1981","journal-title":"Int J Appl Radiat Isot"},{"key":"B113","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1073\/pnas.26.8.483","article-title":"Comparison of the metabolism of iodine and of element 85 (Eka-Iodine)","volume":"26","author":"Hamilton","year":"1940","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1063\/1.1747034","article-title":"Chemical properties of astatine","volume":"17","author":"Johnson","year":"1949","journal-title":"J Chem Physics"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cbr.2012.1292","article-title":"Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted alpha-particle therapy","volume":"28","author":"Guerard","year":"2013","journal-title":"Cancer Biother Radiopharm."},{"key":"B116","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1874471011104030214","article-title":"Chemical and radiochemical considerations in radiolabeling with alpha-emitting radionuclides","volume":"4","author":"Wilbur","year":"2011","journal-title":"Curr Radiopharm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1039\/D0SC05191H","article-title":"Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies","volume":"12","author":"Berdal","year":"2021","journal-title":"Chemical Science."},{"key":"B118","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0883-2889(86)90274-1","article-title":"Organoastatine chemistry. Astatination via electrophilic destannylation","volume":"37","author":"Milius","year":"1986","journal-title":"Int J Rad Appl Instrum A"},{"key":"B119","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0969-8043(95)00285-5","article-title":"Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction","volume":"47","author":"Larsen","year":"1996","journal-title":"Appl Radiat Isot."},{"key":"B120","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2017.01.011","article-title":"Development of a preclinical (211)Rn\/(211)At generator system for targeted alpha therapy research with (211)At","volume":"48","author":"Crawford","year":"2017","journal-title":"Nucl Med Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1874471011104030177","article-title":"Astatine-211: production and availability","volume":"4","author":"Zalutsky","year":"2011","journal-title":"Curr Radiopharm."},{"key":"B122","doi-asserted-by":"publisher","first-page":"20318","DOI":"10.1038\/s41598-019-56272-7","article-title":"Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets","volume":"9","author":"O'Hara","year":"2019","journal-title":"Sci Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"136176","DOI":"10.1016\/j.cej.2022.136176","article-title":"Compact automated apparatus for rapid astatine recovery from nitric acid media: design, application, and impurity characterization","volume":"442","author":"Tereshatov","year":"2022","journal-title":"Chem Engin J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"12025","DOI":"10.1038\/srep12025","article-title":"Automated astatination of biomolecules\u2013a stepping stone towards multicenter clinical trials","volume":"5","author":"Aneheim","year":"2015","journal-title":"Sci Rep."},{"key":"B125","unstructured":"2022"},{"key":"B126","unstructured":"2022"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T11:19:23Z","timestamp":1673003963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":126,"alternative-id":["10.3389\/fmed.2022.1076210"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1076210","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"article-number":"1076210"}}